AstraZeneca PLC (AZN)vsInsulet Corporation (PODD)
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
PODD
Insulet Corporation
$153.22
+4.65%
HEALTHCARE · Cap: $10.37B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1984% more annual revenue ($60.44B vs $2.90B). AZN leads profitability with a 17.2% profit margin vs 10.4%. PODD appears more attractively valued with a PEG of 1.32. PODD earns a higher WallStSmart Score of 73/100 (B).
AZN
Buy64
out of 100
Grade: C+
PODD
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for PODD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Revenue surging 33.9% year-over-year
Earnings expanding 159.0% YoY
Every $100 of equity generates 23 in profit
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Premium valuation, high expectations priced in
Trading at 8.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : PODD
The strongest argument for PODD centers on Revenue Growth, EPS Growth, Return on Equity. Revenue growth of 33.9% demonstrates continued momentum. PEG of 1.32 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : PODD
The primary concerns for PODD are P/E Ratio, Price/Book.
Key Dynamics to Monitor
AZN profiles as a mature stock while PODD is a growth play — different risk/reward profiles.
PODD carries more volatility with a beta of 1.13 — expect wider price swings.
PODD is growing revenue faster at 33.9% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
PODD scores higher overall (73/100 vs 64/100) and 33.9% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Insulet Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?